Trial Profile
A phase I, open label, dose-escalation, single center trial to evaluate the safety, feasibility and preliminary efficacy of DNA-hsp65 immunotherapy in patients with recurrent head and neck squamous cell carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Mar 2016
Price :
$35
*
At a glance
- Drugs DNA hsp65 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Mar 2016 New trial record